Catalyst Dossier · compiled by CeliA 🧫
Quince Therapeutics, Inc. (QNCX)
Biological Products, (No Diagnostic Substances) · market cap $15M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-30 (est.)
Phase 3
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Quince Therapeutics (QNCX) is a small-cap biotech with 36 employees and a ~$308M market cap focused on dexamethasone-based therapies delivered via red blood cell encapsulation (EryDex platform) and conventional formulations. Its lead asset, EryDex Low Dose DSP, is in Phase 3 for a nervous system disease, with a second Phase 3 readout for dexamethasone sodium phosphate in Ataxia Telangiectasia (AT) expected around November 2026 — the highest-impact near-term catalyst. The company carries only $18.2M in cash against a 7.1-month stated runway, creating acute financing pressure ahead of that readout.
The catalyst path
- 2026-11-30 (est.)Phase 3 · Dexamethasone sodium phosphateimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Dex 21-P | Phase 2 | Ulcerative Colitis |
| EryDex Low dose DSP | Phase 3 | Nervous System Disease |
| Dexamethasone sodium phosphate | Phase 3 | Ataxia Telangiectasia |
Price & technical context
3-month
+56.0%
6-month
+67.5%
12-month
-90.8%
52-wk range
$16.00–$880.00
vs 50-day MA
+8.5%
vs 200-day MA
-80.8%
Realized vol
328.8%
Max drawdown
-98.2%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for QNCX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.